Intuitive Surgical, Inc. (ISRG) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Intuitive Surgical develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates a business model combining up-front system sales/leases with recurring revenue from instruments, accessories, and services. As of September 30, 2024, the installed base of da Vinci systems reached approximately 9,539 units, and the Ion system installed base reached approximately 736 units.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2024 | Q3 2023 | YTD 9M 2024 | YTD 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $2,038.1 | $1,743.7 | $5,938.6 | $5,195.8 |
| Gross Profit | $1,373.9 | $1,167.2 | $3,992.0 | $3,452.1 |
| Gross Margin | 67.4% | 66.9% | 67.2% | 66.4% |
| Operating Income | $577.3 | $465.8 | $1,614.0 | $1,316.6 |
| Net Income (Attributable to ISRG) | $565.1 | $415.7 | $1,636.9 | $1,191.8 |
| Diluted EPS | $1.56 | $1.16 | $4.53 | $3.34 |
| Cash, Cash Equivalents & Investments | $8,311.5 | $7,343.2 (Dec 31, 2023) | $8,311.5 | $7,343.2 (Dec 31, 2023) |
| Operating Cash Flow (9M) | $1,592.4 | $1,585.5 | $1,592.4 | $1,585.5 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17% in Q3 2024 compared to Q3 2023, driven by 18% growth in instruments and accessories and 17% growth in systems revenue.
- Procedure Volume: Total da Vinci procedures grew 18% in Q3 2024 (approx. 670,000 procedures), with U.S. growth of 16% and Outside U.S. (OUS) growth of 24%. Ion procedures surged 73% to approx. 25,000.
- System Placements: The company placed 379 da Vinci systems in Q3 2024, up from 312 in Q3 2023. This included 110 placements of the new da Vinci 5 system. Ion placements increased to 58 from 55.
- Operating Expenses: Operating expenses increased 14% to $796.6 million, primarily due to higher headcount, share-based compensation ($176 million in Q3), and legal/litigation costs.
- Interest Income: Interest and other income, net, increased 67% to $93.7 million due to higher interest rates and investment balances.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects continued growth driven by procedure adoption and the rollout of the da Vinci 5 and da Vinci SP systems. Capital expenditures for 2024 are expected to range between $1.0 billion and $1.2 billion, primarily for facilities. The company anticipates funding future growth through operating cash flows.
Risks and Contingencies:
- Legal Proceedings: The company faces ongoing product liability lawsuits and significant antitrust litigation regarding EndoWrist service and repair (e.g., In Re: da Vinci Surgical Robot Antitrust Litigation). A trial for the SIS antitrust case is set for January 2025. Management states it is unable to estimate potential losses for these matters.
- Macroeconomic Factors: Risks include inflation, elevated interest rates, supply chain constraints, and geopolitical conflicts (Russia-Ukraine, Middle East) impacting hospital spending and credit access.
- Regulatory Environment: In China, government quotas and pricing limits on robotic surgery may impact procedure volumes and revenue. In Japan, reimbursement changes are monitored closely.
- Competition: Increased competition from domestic Chinese companies and global rivals (e.g., Medtronic, Johnson & Johnson) is noted.
Investor Verification Checklist
- Antitrust Litigation Status: Monitor the January 2025 trial date for the SIS antitrust case and the class certification hearing for the In Re: da Vinci litigation in January 2025.
- da Vinci 5 Adoption: Verify the commercial ramp-up and supply chain maturity of the da Vinci 5 system, which accounted for 110 placements in Q3.
- China Market Dynamics: Track the impact of the Chinese government's "systematic governance" campaign and pricing limits on system placements and procedure volumes in the region.
- Bariatric Procedure Trends: Assess the sustainability of the modest decline in U.S. bariatric procedures as patients evaluate new drug therapies.
- Inventory Levels: Review the $651 million increase in inventory (YTD) to ensure it aligns with demand forecasts and does not signal future write-downs.